Safety, Tolerability and Pharmacokinetic Characteristics of Singletine(DC407) in Healthy Adult Subjects After Single and Multiple Doses: a Single-center, Randomized, Double-blind, Placebo-controlled, Phase 1 Trial
Latest Information Update: 14 Dec 2023
At a glance
- Drugs DC 407 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Guangzhou JOYO Pharma
Most Recent Events
- 14 Dec 2023 New trial record